Frontiers in Immunology, 2022 Recent studies have indicated the involvement of chemokine-C-motif ligand 1 (XCL1) in nociceptive transmission; however, the participation of its two receptors, canonical chemokine-C-motif receptor 1 (XCR1) and integrin alpha-9 (ITGA9), recently ...
Agata Ciechanowska +7 more
exaly +7 more sources
Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control [PDF]
Frontiers in Immunology, 2019 Cross-presenting Xcr1+CD8α DCs are attractive APCs to target for therapeutic cancer vaccines, as they are able to take up and process antigen from dying tumor cells for their MHCI-restricted presentation to CD8 T cells.
Jeffrey A Hubbell +2 more
exaly +8 more sources
Endocytosis Deficient Murine Xcl1-Fusion Vaccine Enhances Protective Antibody Responses in Mice [PDF]
Frontiers in Immunology, 2019 Targeting antigen to surface receptors on dendritic cells (DCs) can improve antibody response against subunit vaccines. We have previously observed that human XCL1-fusion vaccines target murine Xcr1+ DCs without actively inducing endocytosis of the ...
Arnar Gudjonsson +2 more
exaly +8 more sources
Metamorphic Protein Folding Encodes Multiple Anti-Candida Mechanisms in XCL1 [PDF]
Pathogens, 2021 Candida species cause serious infections requiring prolonged and sometimes toxic therapy. Antimicrobial proteins, such as chemokines, hold great interest as potential additions to the small number of available antifungal drugs.
Acacia F. Dishman +3 more
doaj +6 more sources
The XCL1-XCR1 axis supports intestinal tissue residency and antitumor immunity. [PDF]
J Exp MedTissue-resident memory T cells (TRM) provide frontline protection against pathogens and emerging malignancies. Tumor-infiltrating lymphocytes (TIL) with TRM features are associated with improved clinical outcomes.
Ferry A +11 more
europepmc +6 more sources
XCL1-secreting CEA CAR-T cells enhance endogenous CD8+ T cell responses to tumor neoantigens to confer a long-term antitumor immunity [PDF]
Journal for ImmunoTherapy of CancerBackground Therapeutic efficacy of carcinoembryonic antigen (CEA)-specific chimeric antigen receptor (CAR) T cells against colorectal cancer (CRC) remains limited due to the unique characteristics and distinct microenvironments of tumor tissues.
Kun Chen +10 more
doaj +5 more sources
Blockade of XCL1/Lymphotactin Ameliorates Severity of Periprosthetic Osteolysis Triggered by Polyethylene-Particles [PDF]
Frontiers in Immunology, 2020 Periprosthetic osteolysis induced by orthopedic implant-wear particles continues to be the leading cause of arthroplasty failure in majority of patients.
Tomohiro Onodera +2 more
exaly +7 more sources
Structure-Function Relationship of XCL1 Used for in vivo Targeting of Antigen Into XCR1+ Dendritic Cells [PDF]
Frontiers in Immunology, 2018 XCL1 is the ligand for XCR1, a chemokine receptor uniquely expressed on cross-presenting dendritic cells (DC) in mouse and man. We are interested in establishing therapeutic vaccines based on XCL1-mediated targeting of peptides or proteins into these DC.
Sebastian Voigt, Christian Freund
exaly +8 more sources
The XCL1/XCR1 axis is upregulated in type 1 diabetes and aggravates its pathogenesis [PDF]
JCI InsightType 1 diabetes (T1D) is precipitated by the autoimmune destruction of the insulin-producing β cells in the pancreatic islets of Langerhans. Chemokines have been identified as major conductors of islet infiltration by autoaggressive leukocytes, including
Camilla Tondello +13 more
doaj +5 more sources
Single-cell analysis reveals XCL1+ CD8+ T cells as a therapeutic target in hepatocellular carcinoma [PDF]
Molecular & Cellular OncologyXCL1 (lymphotactin), a C-chemokine primarily produced by activated CD8+ T cells, remains poorly characterized in the context of immunotherapy. Here, we conducted comprehensive analyses based on multiple scRNA-seq datasets to identify the presence of XCL1+
Guowei Li +6 more
doaj +3 more sources